ArticleJournal of robotic surgery2025
Safety and functional outcomes of modified maximum peri-prostatic anatomy preserving-robotic assisted laparoscopic radical prostatectomy base on Da Vinci robot.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety and efficacy of different surgical approaches in single-port robot-assisted radical prostatectomy based on propensity score matching analysis.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
To describe a revised surgical approach for robotic-assisted laparoscopic radical prostatectomy and evaluate its safety, functional outcomes, urinary symptoms, quality of life, and short-term oncological results. A total of 61 patients at a large university hospital underwent modified maximum peri-prostatic anatomy preserving-robotic assisted laparoscopic radical prostatectomy (MPAP-RALP) from June 2019 to June 2022. The median surgery time and blood loss were 257.0 min and 200.0 mL. Three patients had Clavien-Dindo grade II complications, and only one patient had Clavien-Dindo grade III complications. No patients died. 12 (19.7%) patients with surgical margins. 13 (21.3%) and 9 (14.8%) patients had evidence of PSA persistence after 1 month and 6-8 postoperative weeks. Continence rates continued to improve at 1 month (95.1%), 3 months (95.1%), 6 months (96.7%), and 12 months after surgery. No patients had serious urinary symptoms, and 2 (3.3%) patients were dissatisfied after 1 month surgery about quality of life. In conclusion, the modified MPAP-RALP is feasible and can be performed safely by an experienced urologic surgeon. Preliminary evidence suggests that the modified MPAP-RALP facilitates early continence recovery, does not affect surgical margin rates, reduces surgical complications, and enhances quality of life.
Indexed as
Identifiers
41400712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.